You are here

  • Home
  • Archive
  • Volume 30, Issue 2
  • Study of overall survival associated with nintedanib and pirfenidone in patients with idiopathic pulmonary fibrosis: a real-life comparison

Article info

Article menu
Download PDFPDF
PostScript
Letter
Study of overall survival associated with nintedanib and pirfenidone in patients with idiopathic pulmonary fibrosis: a real-life comparison

Authors

  1. Correspondence to Dr Ludovica Mazzoleni, UOC Farmacia, ASST Santi Paolo e Carlo, Milano 20142, Italy; lmazzo2004{at}yahoo.it
View Full Text

Citation

Mazzoleni L, Borsino C, Zovi A
Study of overall survival associated with nintedanib and pirfenidone in patients with idiopathic pulmonary fibrosis: a real-life comparison
European Journal of Hospital Pharmacy 2023;30:e11.

Publication history

  • First published January 21, 2022.
Online issue publication 
February 21, 2023

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© European Association of Hospital Pharmacists 2023. No commercial re-use. See rights and permissions. Published by BMJ.